Vertex, Inc. (NASDAQ:VERX) Q4 2025 Earnings Call Transcript February 11, 2026 Vertex, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $0.17. Operator: Good day, and ...

For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Thursday reported fourth-quarter net income of $1.19 billion. The Boston-based company said it had profit of $4.65 per share. Earnings ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Q4 2025 Earnings Call February 18, 2026 9:00 AM ESTCompany ParticipantsRoushan Ahmadi-Zenooz - Senior Vice President of ...

CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its ...

SHENZHEN, GUANGDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- Walking through the neon-drenched streets of a ...

Gemini Auto-Browse in Chrome automates shopping, forms, and research, including fixing size errors in carts so you save time.

Whatever you choose, gardeners will undoubtedly appreciate a gift that nurtures their passion and enhances their gardening ...